Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis?
Background and aim. DNA methylation plays a critical role in the control of important cellular processes. The present study assessed the impact of promoter methylation (PM) of some genes on the antiviral response to antiviral therapy and it’s relation to the presence of fibrosis in HCV-4 infected pa...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-09-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119312517 |
id |
doaj-d06ec7c118d1406dbcac1df6bc55c0eb |
---|---|
record_format |
Article |
spelling |
doaj-d06ec7c118d1406dbcac1df6bc55c0eb2021-06-09T05:53:50ZengElsevierAnnals of Hepatology1665-26812014-09-01135518524Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis?Abdel-Rahman N. Zekri, M.Sc., Ph.D.0Ahmed M. Raafat1Suzan Elmasry2Abeer A. Bahnassy3Yasmin Saad4Hamed A. Dabaon5Mohamed El-Kassas6Hend I. Shousha7Auhood A. Nassar8Mohamed Ale EL-Dosouky9Nehal Hussein10Molecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; Correspondence and reprint request:Molecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, EgyptBiochemistry Department, Faculty of Science, Cairo University, Cairo, EgyptMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, EgyptDepartment of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, EgyptOrganic Chemistry Department, Faculty of Science, Cairo University, Cairo, EgyptDepartment of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, EgyptDepartment of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, EgyptMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, EgyptBiochemistry Department, Faculty of Science, Cairo University, Cairo, EgyptMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, EgyptBackground and aim. DNA methylation plays a critical role in the control of important cellular processes. The present study assessed the impact of promoter methylation (PM) of some genes on the antiviral response to antiviral therapy and it’s relation to the presence of fibrosis in HCV-4 infected patients from Egypt.Material and methods. Clinical, laboratory and histopathological data of 53 HCV-4 infected patients who were subjected to combined antiviral therapy were collected; patients were classified according to their response to treatment and the fibrosis status. The methylation profiles of the studied groups were determined using the following genes: APC, P14ARF, P73, DAPK, RASSF1A, and O6MGMT in patients’ plasma.Results. O6MGMT and P73 showed the highest methylation frequencies (64.2 and 50.9%) while P14 showed the lowest frequency (34%). Sustained virological response (SVR) was 54.7%with no significant difference in clinico-pathological or laboratory features between the studied groups. PM of O6MGM was significantly higher in non-responders (p value 0.045) while DAPK showed high methylation levels in responders with no significance (p value: 0.09) andPM of RASSF1A was significantly related to mild fibrosis (p value: 0.019). No significant relations were reported between PM of any of the studied genes and patients’ features.Conclusion. PM of some Tumor Suppressor genes increases in chronic active HCV-4. However, only 06MGMT can be used as a predictor of antiviral response and RASSF1A as a marker of marked fibrosis in this small set of patients. An extended study, including more patients is required to validate the results of this preliminary study.http://www.sciencedirect.com/science/article/pii/S1665268119312517HCVAntiviral responsePromoter methylation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdel-Rahman N. Zekri, M.Sc., Ph.D. Ahmed M. Raafat Suzan Elmasry Abeer A. Bahnassy Yasmin Saad Hamed A. Dabaon Mohamed El-Kassas Hend I. Shousha Auhood A. Nassar Mohamed Ale EL-Dosouky Nehal Hussein |
spellingShingle |
Abdel-Rahman N. Zekri, M.Sc., Ph.D. Ahmed M. Raafat Suzan Elmasry Abeer A. Bahnassy Yasmin Saad Hamed A. Dabaon Mohamed El-Kassas Hend I. Shousha Auhood A. Nassar Mohamed Ale EL-Dosouky Nehal Hussein Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? Annals of Hepatology HCV Antiviral response Promoter methylation |
author_facet |
Abdel-Rahman N. Zekri, M.Sc., Ph.D. Ahmed M. Raafat Suzan Elmasry Abeer A. Bahnassy Yasmin Saad Hamed A. Dabaon Mohamed El-Kassas Hend I. Shousha Auhood A. Nassar Mohamed Ale EL-Dosouky Nehal Hussein |
author_sort |
Abdel-Rahman N. Zekri, M.Sc., Ph.D. |
title |
Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? |
title_short |
Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? |
title_full |
Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? |
title_fullStr |
Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? |
title_full_unstemmed |
Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? |
title_sort |
promotor methylation: does it affect response to therapy in chronic hepatitis c (g4) or fibrosis? |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2014-09-01 |
description |
Background and aim. DNA methylation plays a critical role in the control of important cellular processes. The present study assessed the impact of promoter methylation (PM) of some genes on the antiviral response to antiviral therapy and it’s relation to the presence of fibrosis in HCV-4 infected patients from Egypt.Material and methods. Clinical, laboratory and histopathological data of 53 HCV-4 infected patients who were subjected to combined antiviral therapy were collected; patients were classified according to their response to treatment and the fibrosis status. The methylation profiles of the studied groups were determined using the following genes: APC, P14ARF, P73, DAPK, RASSF1A, and O6MGMT in patients’ plasma.Results. O6MGMT and P73 showed the highest methylation frequencies (64.2 and 50.9%) while P14 showed the lowest frequency (34%). Sustained virological response (SVR) was 54.7%with no significant difference in clinico-pathological or laboratory features between the studied groups. PM of O6MGM was significantly higher in non-responders (p value 0.045) while DAPK showed high methylation levels in responders with no significance (p value: 0.09) andPM of RASSF1A was significantly related to mild fibrosis (p value: 0.019). No significant relations were reported between PM of any of the studied genes and patients’ features.Conclusion. PM of some Tumor Suppressor genes increases in chronic active HCV-4. However, only 06MGMT can be used as a predictor of antiviral response and RASSF1A as a marker of marked fibrosis in this small set of patients. An extended study, including more patients is required to validate the results of this preliminary study. |
topic |
HCV Antiviral response Promoter methylation |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119312517 |
work_keys_str_mv |
AT abdelrahmannzekrimscphd promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT ahmedmraafat promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT suzanelmasry promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT abeerabahnassy promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT yasminsaad promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT hamedadabaon promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT mohamedelkassas promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT hendishousha promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT auhoodanassar promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT mohamedaleeldosouky promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis AT nehalhussein promotormethylationdoesitaffectresponsetotherapyinchronichepatitiscg4orfibrosis |
_version_ |
1721388873803628544 |